BGI Genomics (SHE:300676) secured the approval of China's drug regulator for changes to its NIFTY prenatal testing kit.
The changes add the NIFTY-B model and expand instrument compatibility to include the DNBSEQ-G99 sequencer, according to a Thursday filing with the Shenzhen bourse. The kit is used to screen for fetal chromosomal abnormalities.
Shares of the genomics services provider closed 5% lower Friday.